Anita Dushyanth
Stock Analyst at Berenberg
(2.60)
# 2,038
Out of 5,169 analysts
4
Total ratings
75%
Success rate
15.74%
Average return
Main Sectors:
Stocks Rated by Anita Dushyanth
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| URGN UroGen Pharma | Initiates: Buy | $20 | $18.48 | +8.23% | 1 | Apr 27, 2022 | |
| SERA Sera Prognostics | Initiates: Buy | $13 | $1.91 | +580.63% | 1 | Apr 27, 2022 | |
| BTAI BioXcel Therapeutics | Initiates: Buy | $1,200 | $1.65 | +72,627.27% | 1 | Apr 9, 2021 | |
| PCRX Pacira BioSciences | Initiates: Buy | $93 | $22.02 | +322.34% | 1 | Apr 9, 2021 |
UroGen Pharma
Apr 27, 2022
Initiates: Buy
Price Target: $20
Current: $18.48
Upside: +8.23%
Sera Prognostics
Apr 27, 2022
Initiates: Buy
Price Target: $13
Current: $1.91
Upside: +580.63%
BioXcel Therapeutics
Apr 9, 2021
Initiates: Buy
Price Target: $1,200
Current: $1.65
Upside: +72,627.27%
Pacira BioSciences
Apr 9, 2021
Initiates: Buy
Price Target: $93
Current: $22.02
Upside: +322.34%